385 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author엄지은-
dc.date.accessioned2016-06-20T01:53:41Z-
dc.date.available2016-06-20T01:53:41Z-
dc.date.issued2012-01-
dc.identifier.citationLUNG CANCER, v. 75, Page. 82-88en_US
dc.identifier.issn0169-5002-
dc.identifier.urihttp://www.sciencedirect.com/science/article/pii/S0169500211003199-
dc.description.abstractPurpose Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this randomized, single-center, non-comparative phase II trial, the efficacy and safety of gefitinib and erlotinib was evaluated as the second-line therapy for advanced non-small cell lung cancer (NSCLC). Patients and methods Patients with locally advanced, metastatic stage IIIB/IV NSCLC who failed first-line chemotherapy and had either EGFR mutation or at least two out of three clinical factors associated with higher incidence of EGFR mutations (female, adenocarcinoma histology, and never-smoker) were eligible. Results A total of 96 (48 per arm) patients were randomly assigned to gefitinib- or erlotinib-arm, respectively. Baseline characteristics were well-balanced between the two arms. The response rates (RR) were 47.9% in the gefitinib arm and 39.6% in the erlotinib arm. Median PFS was 4.9 months (95% CI, 1.3–8.5) in the gefitinib arm and 3.1 months (95% CI, 0.0–6.4) in the erlotinib arm. The most common grade 3/4 toxicity was skin rash. Exploratory analyses showed that there was no significant difference in RR and PFS in the gefitinib arm compared to the erlotinib arm (RR (%) 47.9 vs. 39.6, p = 0.269; median survival (months) 4.9 vs. 3.1, p = 0.336). There was no significant difference in QOL between the two arms. Conclusion Both gefitinib and erlotinib showed effective activity and tolerable toxicity profiles as second-line treatment for the selected population of NSCLC. We may consider conducting a phase III trial to directly compare the efficacy and toxicity between gefitinib and erlotinib in an enriched patient population.-
dc.description.sponsorshipThis study was supported by IN-SUMG Foundation for Medical Research (CA98711).-
dc.publisherELSEVIER IRELAND LTDen_US
dc.subjectGefitinib-
dc.subjectErlotinib-
dc.subjectNon-small cell lung cancer-
dc.titleRandomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapyen_US
dc.typeArticleen_US
dc.relation.volume75-
dc.identifier.doi10.1016/j.lungcan.2011.05.022-
dc.relation.page82-88-
dc.relation.journalLUNG CANCER-
dc.contributor.googleauthorKim, Seung Tae-
dc.contributor.googleauthorUhm, Ji Eun-
dc.contributor.googleauthorLee, Jeeyun-
dc.contributor.googleauthorSun, Jong-mu-
dc.contributor.googleauthorSohn, Insuk-
dc.contributor.googleauthorKim, Seon Woo-
dc.contributor.googleauthorJung, Sin-Ho-
dc.contributor.googleauthorPark, Yeon Hee-
dc.contributor.googleauthorAhn, Jin Seok-
dc.contributor.googleauthorPark, Keunchil-
dc.relation.code2012206399-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE